Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)

por Kushner, Robert F, Garvey, W Timothy, Hesse, Dan, Koroleva, Anna, Lim, Soo, Lingvay, Ildiko, Mosenzon, Ofri, Wallenstein, Signe O R, Wadden, Thomas A, le Roux, Carel W
Publicado 2021

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)

por Mosenzon, Ofri, Garvey, W Timothy, Hesse, Dan, Koroleva, Anna, Kushner, Robert F, Lim, Soo, Lingvay, Ildiko, Wallenstein, Signe O R, Wadden, Thomas A, Le Roux, Carel W
Publicado 2021